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idiopathic PA hypertension (IPAH) not responding optimally to medical therapy.Background Baroreceptors and sympathetic nerve ﬁbers are localized in or near the bifurcation area of the main PA. We
previously demonstrated that PADN completely abolished the experimentally elevated PA pressure responses to
occlusion of the left interlobar PA.Methods Of a total of 21 patients with IPAH, 13 patients received the PADN procedure, and the other 8 patients who refused
the PADN procedure were assigned to the control group. PADN was performed at the bifurcation of the main PA, and
at the ostial right and left PA. Serial echocardiography, right heart catheterization, and a 6-min walk test (6MWT)
were performed. The primary endpoints were the change of PA pressure (PAP), tricuspid excursion (Tei) index, and
6MWT at 3 months follow-up.Results Compared with the control group, at 3 months follow-up, the patients who underwent the PADN procedure showed
signiﬁcant reduction ofmeanPAP (from555mmHg to365mmHg, p<0.01), and signiﬁcant improvement of the
6MWT (from 324 21m to 491 38m, p< 0.006) and of the Tei index (from 0.7 0.04 to 0.50 0.04, p< 0.001).Conclusions We report for the ﬁrst time the effect of PADN on functional capacity and hemodynamics in patients with IPAH not
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Cardiology FoundationIdiopathic pulmonary arterial hypertension (IPAH) is
characterized by elevations of mean pulmonary artery (PA)
pressure (PAP) and pulmonary vascular resistance (PVR)
(1). The pathogenesis of IPAH was believed to be due to an
imbalance between locally produced vasodilators and vaso-
constrictors (2). Recent studies have demonstrated that
vascular wall remodeling also contributes to elevated PVR
(3). Up to now, the role of neural reﬂex in the mediation and
development of IPAH has not been speciﬁcally investigated.t, Nanjing First Hospital, Nanjing Medical
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3; revised manuscript received May 15, 2013,In 1962, Osorio et al. (4) reported the existence of a pul-
mopulmonary baroreceptor reﬂex that originates in the
large pulmonary branches, with neither the afferent nor
the efferent ﬁbers belonging to the vagus nerve. In 1980,
these ﬁndings were again conﬁrmed by Juratsch et al. (5)
and Baylen et al. (6). More recently, our animal study (7)
See page 1101
demonstrated that PA denervation (PADN) could com-
pletely abolish the increment of PAP induced by balloon
occlusion at the interlobar segment but not at the basal
trunk. On the basis of such ﬁndings, we designed a ﬁrst-in-
man study to test the safety and efﬁcacy of PADN by
inducing local injury/destruction to the baroreceptor or
sympathetic nervous ﬁbers in patients with IPAH who did
not respond optimally to current medical therapy.
Table 1 Baseline Characteristics in All Patients
PADN Group
(n ¼ 13)
Control Group
(n ¼ 8)
Age, yrs 40  16 41  10
Male 9 (69) 4 (50)
Height, cm 164  5 165  5
Weight, kg 63  6 65  7
Systolic blood pressure, mm Hg 115  9 114  9
Diastolic blood pressure, mm Hg 68  7 71  5
Heart rate, beats/min 92  6 90  3
Time interval, yrs
From symptom to diagnosis 3.5  1.1 3.4  1.2
Clinical presentation
Dyspnea 13 (100) 8 (100)
Chest pain 10 (77)* 4 (50)
Syncope 3 (23) 2 (25)
Fatigue 13 (100) 8 (100)
From starting medication to PADN 3.3  0.2 3.3  0.1
Drugs used following diagnosis
Oxygen 13 (100) 8 (100)
Monotherapy 0 0
Combination of at least 2 drugs 13 (100) 8 (100)
Diuretics 13 (100) 8 (100)
Beraprost 13 (100) 8 (100)
Bosentan 3 (23) 2 (25)
Sildenaﬁl 11 (85) 5 (63)
Anticoagulant 13 (100) 7 (88)
Cholesterol, mml/l 2.1  0.4 2.1  0.3
Low-density cholesterol, mmol/l 1.1  0.2 1.2  0.2
Fasting blood glucose, mmol/l 3.6  0.5 3.5  0.5
Serum creatinine, mmol/l 63.5  5.4 64.2  6.8
White blood cells,  109/l 4.3  0.1 4.3  0.2
Values are mean  SD or n (%). *p ¼ 0.033, compared with the control group.
PADN ¼ pulmonary artery denervation; PAH ¼ pulmonary artery hypertension.
Abbreviations
and Acronyms
6MWT = 6-min walk test
CO = cardiac output
IPAH = idiopathic pulmonary
arterial hypertension
MPA = main pulmonary
artery
NT-BNP = N-terminal brain
natriuretic peptide
PA = pulmonary artery
PADN = pulmonary artery
denervation
PAH = pulmonary artery
hypertension
PAOP = pulmonary artery
occlusive pressure
PAP = pulmonary artery
pressure
PVR = pulmonary vascular
resistance
RA = right atrium/atrial
RV = right ventricle/
ventricular
Tei = tricuspid excursion
index
TPG = transpulmonary
pressure gradient
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Patient population. Patients with IPAH (deﬁned as a mean
PAP 25 mm Hg at rest) not responding optimally to
current medical therapy (deﬁned as a reduction of<5mmHg
in the resting mean PAP during medication, or unchanged 6-
min walk test (6MWT) deﬁned as increment of 6MW
distance <50 m) were eligible for the study. A total of 22
patients were screened. One patient was excluded after
a positive adenosine test (deﬁned as a decrease of the mean
PAP 10 mm Hg to an absolute level of <40 mm Hg (8),
measured by right heart catheterization). Eight patients
refused to consent and were assigned to the control group.
These patients continued to receive the same medical therapy
as before enrollment. Thirteen patients were included in the
study group.
Medical treatment before enrollment. Before enrollment,
all 21 patients received a diuretic (hydrochlorothiazide at
a dose of 12.5 mg to 25 mg, once daily, and/or spi-
ronolactone at a dose of 20 mg to 40 mg, once daily) and
beraprost (120 mg, 4 times daily) (Table 1), with either
sildenaﬁl (20 mg, 3 times a day) or bosentan (120 mg, twice
daily) or digoxin (0.125 mg, once daily).All patients were informed that
PADN was only tested previously
in an animal study that showed that
PADN could abolish the elevated
PAP response to occlusion of the
left interlobar PA by a balloon
inﬂation (7). According to the
study protocol, the risk of medica-
tions being withdrawn after the
PADNprocedure was described to
each patient. The patients were
also informed that they had the
right to withdraw their consent at
any time. The study protocol was
presented in detail to the institu-
tional review board and was
approved by the institutional re-
view board and ethics committee.
Written consent was obtained
from all patients.
Assessment of N-terminal brain
natriuretic peptide level. Blood
samples were obtained for N-
terminal brain natriuretic peptide
(NT-BNP) levels before, imme-
diately after the PADN proce-
dure, and at 24 h, 1 week, 1
month, 2 months, and 3 months
following the PADN procedure.
Assessment of functional capacity. Functional capacity (9)
was determined by the 6MWT, followed by an assessment
of dyspnea using the Borg scale (10). The 6MWT was
performed at 1 week, 1 month, 2 months, and 3 months
following the PADN procedure. The World Health Orga-
nization classiﬁcation (11) at rest and during exercise was
recorded by a physician who was blinded to the study design.
Echocardiographic assessment. Echocardiography was
performed at 1 week, 1 month, 2 months, and 3 months
following the procedure. Echocardiographic studies were
done using a Vivid 7 ultrasound system with a standard
imaging transducer (General Electric Co., Easton Turnpike,
Connecticut). All of the echocardiograms were performed
and interpreted in the medical university’s echocardiographic
laboratory. All of the measurements were performed
following the recommendations of the American Society of
Echocardiography (12). Digital echocardiographic data that
contained a minimum of 3 consecutive beats (or 5 beats in
cases of atrial ﬁbrillation) were acquired and stored. Right
ventricular (RV) systolic pressure is equal to systolic PAP in
the absence of pulmonary stenosis. Systolic PAP is equal to
the sum of the right atrial (RA) pressure and the RV-to-RA
pressure gradient during systole. RA pressure was estimated
based on the echocardiographic features of the inferior vena
cava and assigned a standard value (13). The RV-to-RA
pressure gradient was calculated as 4vt
2 using the modiﬁed
Bernoulli equation, where vt is the velocity of the tricuspid
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according to the velocity of the pulmonary regurgitation jet
in m/s. The tricuspid excursion index (Tei) (14) is deﬁned as
(A  B)/B, where A is the time interval between the end
and the onset of tricuspid annular diastolic velocity, and B is
the duration of tricuspid annular systolic velocity (or the RV
ejection time). PA compliance for patients was calculated as
the stroke volume divided by pulse pressure (systolic PAP
minus diastolic PAP).
Right heart catheterization. Hemodynamic measurements
and blood oxygen pressure/saturation determinations from
the RA, RV, and PA were done before and immediately
after the PADN procedure. These measurements were
repeated at 24 h and 3 months.
Procedure. A 7-F ﬂow-directed Swan-Ganz catheter
(131HF7, Baxter Healthcare Corp., Irvine, California) was
inserted into an internal jugular or subclavian vein.
Measurements of resting RA pressure, RV pressure, systolic/
diastolic/mean PAP, PA occlusive pressure (PAOP), cardiac
output (CO) (using the thermodilution method), and mixed
venous oxygen saturation were recorded. The PVR [PVR ¼
(mean PAP  PAOP)/CO] and transpulmonary pressure
gradient (TPG ¼ mean PAP  PAOP) were then calcu-
lated. All of the measurements were recorded at the end of
expiration. Five criteria (15–17) were used to evaluate
whether a PAOP measurement was valid: 1) the PAOP was
less than the diastolic PAP; 2) the tracing was comparable to
the atrial pressure waveform; 3) the ﬂuoroscopic imageFigure 1 A Dedicated 7.5-F Triple-Function Catheter
(A) The catheter had a tapered (to 5-F) circular tip with 10 pre-mounted electrodes (each
connected with a connect-cable and a connect-box (C). There are 10 knobs on the surface
ablation catheter. Sequential ablation was performed by selecting the knob on the generexhibited a stationary catheter following inﬂation; 4) free
ﬂow was present within the catheter (ﬂush test); and 5)
highly oxygenated blood (capillary) was obtained from the
distal portion in the occlusion position. If the PAOP
measurement was unreliable, the left ventricular end-diastolic
pressure was then measured and used rather than the PAOP.
The blood samples from the superior vena cava and PA were
obtained for the measurements of oxygen pressure and
saturation.
Equipment. A dedicated 7.5-F multiple-function (tem-
perature sensing and ablation) catheter (PADN, patent
application in progress) consisted of 2 parts: catheter shaft
and handle (Fig. 1A). This catheter had a tapered (to 5-F)
circular tip with 10 pre-mounted electrodes (separated from
each other by 2 mm) (Fig. 1B). The circular tip had an outer
diameter of 20 mm, 25 mm, 30 mm, 35 mm, 40 mm, and
45 mm, respectively. The “connect” cable linked the handle
to the “connect” box (Fig. 1C). There were 3 ports (Fig. 1D)
on either side of the connect box: “Catheter” was for the
connection of the cable and the catheter handle, “RF” was
for connecting with all kinds of radiofrequency generators
used in the market, and “ECG” was for connecting with
electrocardiogram monitoring equipment. On the surface of
the “connect” box, there was 1 button marked by numbers 1
to 10 and “OFF” and “NULL.” Numerical buttons indicated
the location of each electrode on the circular tip of the
catheter. When a whole system was set up (Fig. 1E), turning
the numerical button on the connect box to “1” wouldelectrode has a width of 0.75mm and is separated by 2 mm [B]). Electrodes are
of connect-box (D), and each is consistent with the electrode on the circular tip of the
ator after the whole system is set up (E).
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electrode at the catheter tip.
PADN procedure. A baseline PA angiography was per-
formed to identify the PA bifurcation level and calculate the
PA diameter (Figs. 2A to 2C). An 8-F long sheath was
inserted through the femoral vein and advanced to the main
PA (MPA) (Fig. 2A). The PADN catheter was advanced
along this long sheath (Fig. 2B). After gently withdrawing
the sheath and pushing the PADN catheter, the circular tip
would be released from the sheath (Fig. 2C). Then, by
slightly rotating and pushing the handle in a clockwise
direction, the circular tip would be positioned at the ostium
of the left PA (Level 1 of ablation, <2 mm distal to oriﬁce,
(Fig. 2D). After ablation at this level, counterclockwise
rotation and withdrawing the handle would allow the circular
tip to slide down to the distal bifurcation area of the MPA
(Level 2 of ablation,<2mm proximal to the bifurcation level)
(Fig. 2E). Finally, continuously rotating and pushing the
handle was performed until the circular tip jumped into Level
3 of ablation (<2 mm distal to the ostial right PA) (Fig. 2F).
Three criteria were used to ensure that the electrodes were
tightly in contact with the endovascular surface: 1) strong
manual resistance when rotating the handle; 2) inability to
advance distally (Fig. 2G) or ease in, withdrawing proximally
(Fig. 2H); and 3) angiographic conﬁrmation. FollowingFigure 2 An 8-F Long Sheath Was Inserted Through the Femoral Vei
(A) The same patient as in Figure 1 is shown. The PADN catheter was advanced along this
the circular tip would be released from the sheath (C). Then, slight clockwise rotation an
ablation, <2 mm distal to oriﬁce [D]). After ablation at Level 1, counterclockwise rotation
bifurcation area of MPA (Level 2 of ablation, <2 mm proximal to the bifurcation level [E]).
tip jumped into the Level 3 of ablation (<2 mm distal to ostial right PA [F]). When the electr
distally (G) or to ease in withdrawing proximally (H).these conﬁrmations, ablation would begin from the 1st to the
10th electrode at Level 1 and then at Levels 2 and 3.
Following the ﬁrst round of ablation at each level, the cath-
eter tip was gently withdrawn, rotated, and re-advanced to
ensure that the entire diameter of the vessel axis was being
ablated.
The following ablation parameters were programmed
at each level: temperature >50C, energy ¼ 10 W, and
time ¼ 60 s. The procedure would be stopped if the patient
complained of intolerable chest pain. The electrocardiogram
and hemodynamic pressure were monitored and continu-
ously recorded throughout the procedure. Procedural success
was deﬁned as a reduction in the mean PAP 10 mm Hg
(as measured by the Swan-Ganz catheter), and there were no
complications. The patients were monitored in the cardiac
care unit for at least 24 h after the PADN procedure.
Peri-procedural medications. An intravenous bolus of
5,000 U of heparin was given immediately following the
insertion of the venous sheath. An additional approximately
2,000 to 3,000 U of heparin was added if the procedural
time was greater than 1 h. Following the procedure, oral
warfarin was prescribed and adjusted according to the
international normalized ratio to be between 1.5 and 2.5 for
all patients. If there were contraindications for warfarin,
aspirin (100 mg/day) and clopidogrel (75 mg/day) weren and Advanced to the MPA
long sheath (B). After gently withdrawing the sheath and pushing the PADN catheter,
d pushing the handle would allow the circular tip into the ostial left PA (Level 1 of
and withdrawing of the handle would allow the circular tip to slide down to the distal
Finally, continuously rotation and pushing the handle was performed until the circular
odes tightly contacted the inner arterial surface, there existed the inability to advance
Table 2 Echocardiographic Measurements in 2 Groups
Before
Following PADN
Post 24 H 1 Week 1 Month 2 Months 3 Months
SPAP, mm Hg
PADN group 86  5* 70  4 70  6 70  6 69  6 71  6 72  7
Control group 86  8* d 84  9* 84  8* 85  9* 83  7* 83  9*
MPAP, mm Hg
PADN group 38  6y 24  5 24  4 25  5 23  4 26  5 26  6*
Control group 37  7*  36  5* 36  5* 37  5* 35  5* 35  6*
Tei
PADN group 0.7  0.04x 0.5  0.04z 0.4  0.04 0.5  0.04z 0.4  0.05 0.4  0.04 0.5  0.04z
Control group 0.7  0.04 d 0.7  0.04x 0.7  0.04x 0.7  0.05x 0.7  0.05x 0.7  0.06x
Pericardial-effusion depth, mm
PADN group 3.5  0.8* 2.7  0.5 2.8  0.7 2.4  0.5 1.4  0.5 0.7  0.2 0.7  0.4
Control group 3.5  0.7* d 3.3  0.9* 3.4  0.7* 3.4  0.7* 3.4  0.7* 3.4  0.7*
PA compliance
PADN group 0.2  0.1* 0.4  0.1 0.4  0.1 0.4  0.1 0.4  0.1 0.4  0.1 0.4  0.1
Control group 0.2  0.1* d 0.2  0.1* 0.2  0.1* 0.2  0.1* 0.2  0.1* 0.2  0.1*
Values are mean  SD. *p < 0.001, compare with following PADN. yp < 0.04, compared with following PADN. zp < 0.001, compared with before PADN. xp < 0.03, compared with following PADN at 24 h,
1 month, and 2 months.
MPAP ¼ mean pulmonary artery pressure; PA ¼ pulmonary artery; PADN ¼ pulmonary artery denervation; SPAP ¼ systolic pulmonary artery pressure; Tei ¼ tricuspid excursion index.
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1096prescribed indeﬁnitely. Immediately after the PADN pro-
cedure, all medications (diuretics, sildenaﬁl, bosentan, be-
raprost, and digoxin) were discontinued in the study group;
the use of supplemental oxygen was left to the physician’s
discretion.
For patients in the control group, all medications that
were previously prescribed before screening were continued.
Their doses were adjusted and left to the physician’s
discretion.
Endpoints. The primary endpoints were improvement of
functional capacity by the 6MWT and mean PAP at 3
months. Clinical adverse events (including PA perforation/
dissection, acute thrombus formation in the PA, all-cause
death, rehospitalization due to PAH, and lung trans-
plantation) served as secondary endpoints and were assessed
by an independent event committee.
Deﬁnitions. PAH was deﬁned as a resting mean PAP 25
mm Hg. Normal PAOP is between 6 and 12 mm Hg. The
normal TPG is 12 mm Hg. Pre-capillary PAH was
deﬁned as a mean PAP 25 mm Hg in association with
PAOP 15 mm Hg and PVR >3 Woods units. Post-
capillary PAH was deﬁned as a mean PAP 25 mm Hg
in association with PAOP >15 mm Hg and a PVR 3
Woods unit (15,16).
Statistical analysis. Continuous variables are expressed as
mean  SD. The normality test for all of the continuous
variables was performed using Kolmogorov-Smirnov and
Shapiro-Wilk tests. Differences in continuous variables
between different time points in the PADN group or
between the PADN and control groups were analyzed using
paired-sample Student t tests or Wilcoxon rank sum tests, as
appropriate. The categorical variables were compared using
the Fisher exact test. Statistical signiﬁcance was deﬁned as
a 2-sided p value < 0.05. All of the analyses were performedusing the statistics program SPSS version 16.0 (SPSS
Institute, Chicago, Illinois).Results
Baseline characteristics. Between March and May 2012,
a total of 21 patients with PAH not responding optimally to
current medical treatment were included (Table 1).
All patients presented with dyspnea and fatigue. Patients
in the PADN group had more frequent chest pain (77%),
compared with 50% in the control group (p ¼ 0.033). The
average time interval between the onset of symptom to
diagnosis was 3.5 years. All patients did not respond opti-
mally to current medical treatment after an average of 3.3
years combination of therapy using at least 2 drugs.
Echocardiographic measurements. Baseline echocardio-
graphic variables were comparable between the 2 groups
(Table 2). After 3 months treatment, there were no signif-
icant differences in echocardiographic measurements in the
control group.
PADN procedure was associated with signiﬁcant reduc-
tion of the systolic PAP and mean PAP through the 3
months follow-up. The size of the pericardial effusion
(thickness of the ﬂuid layer) was reduced from 3.5  0.8 mm
at baseline to 2.7  0.5 mm (p < 0.001) immediately
following the PADN procedure. This metric was decreased
to 0.7  0.4 mm at the 3-month follow-up (p < 0.001).
Importantly, the RV Tei index was signiﬁcantly improved
from 0.7  0.04 at baseline to 0.5  0.04 (p < 0.001) at 3
months.
Right heart catheterization. At baseline, there were no
differences in hemodynamic measurements between the
PADN and control groups (Table 3). Procedural success
was achieved in 12 (92.3%) patients. Procedural failure
Table 3 Hemodynamic Measurements by Right Heart Catheterization
Before Intervention
Following PADN
Post 24 H 3 Months
SPAP, mm Hg
PADN group 86  8* 72  5 70  5 71  6
Control group 86  7* d d 86  7*
MPAP, mm Hg
PADN group 55  5* 39  7 36  5 36  5
Control group 53  5* d d 50  5*
PVR, dyne $ s $ cm5
PADN group 1,883  281 1,150  208y 876  154z 763  162x
Control group 1,877  275 d d 1,847  239k
RVP, mm Hg
PADN group 85  7z 71  6 70  5 69  6
Control group 86  8z d d 85  7z
RAP, mm Hg
PADN group 4  2 5  2 5  3 5  2
Control group 5  2 d d 5  2
PAOP, mm Hg
PADN group 8  2 8  3 8  4 8  3
Control group 7  3 d d 7  4
TPG, mm Hg
PADN group 36  6* 30  5 27  4 28  5
Control group 42  6* d d 34  6*
Cardiac output (l/min $ m2)
PADN group 2.0  0.2 2.6  0.1 2.8  0.2 2.8  0.3
Control group 2.1  0.1 2.1  0.2 2.1  0.1 2.2  0.2
PA O2 saturation, %
PADN group 42  7* 51  6 51  6 52  7
Control group 42  5 43  5 43  5 43  6
Values are mean  SD. *p < 0.001, compared with following PADN. yp < 0.05, compared with before PADN. zp < 0.003, compared with following
PADN. xp < 0.001, compared with before PADN. kp < 0.001, compared with 3 months in following PADN.
PAOP ¼ pulmonary artery occlusive pressure; PVR ¼ pulmonary vessel resistance; RAP ¼ right atrial pressure; RVP ¼ right ventricular pressure;
TPG ¼ transpulmonary pressure gradient; other abbreviations as in Table 2.
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1 patient. This patient developed intolerable chest pain
induced by the PADN procedure after ablation of the ostial
left PA branch. The procedure was stopped for this patient.
Immediately following the PADN procedure, the systolic
PAP and mean PAP signiﬁcantly decreased from a baseline
of 86  8 mm Hg to 72  5 mm Hg (p < 0.01) and from
55  5 mm Hg to 39  7 mm Hg (p < 0.01), respectively.
These reductions were maintained through 3 months
follow-up. Following the reduction of PAP, CO increased
signiﬁcantly (from2.0 0.2 l/min $m2 to2.8 0.3 l/min $m2,
p < 0.001), leading to the signiﬁcant reduction of TPG
and PVR and signiﬁcant increment of venous O2 saturations
in PA.
PA compliance. In the PADN group, PA compliance
increased signiﬁcantly from 0.20  0.04 ml/mm Hg at
baseline to 0.38 0.06 ml/mm Hg at 3 months (p < 0.001),
and this remained unchanged in the control group.
Assessment of functional capacity. In the PADN group,
the baseline NT-BNP was 2,005  442 pg/ml, which
was signiﬁcantly reduced to 822  201 (p ¼ 0.003) at 3
months following the procedure (Table 4). After 1 week, the6MW distance increased signiﬁcantly from a baseline of
324  21 m to 459  42 m (p ¼ 0.009) at 1 month, 487 
47 m (p ¼ 0.004) at 2 months, and 491  38 m (p ¼ 0.004)
at 3 months. This improvement was associated with sig-
niﬁcant improvements in the World Health Organization
class and BORG score. There was no improvement in either
6MW distance or functional classes in the control group.
Clinical follow-up. In the PADN group, all medications
were discontinued except for the oral anticoagulant (with
1 patient also on diuretics). Three patients (23%) needed
supplemental oxygen as required before the procedure.
No PA perforation/dissection/aneurysm or acute thrombus
formation in the PA for the PADN group was observed.
There were no patients requiring lung transplantation in
either group. By contrast, rehospitalization was required in 5
patients (62.5%) in the control group, and none in the
PADN group (p < 0.001).
All patients had chest pain during the PADN procedure,
with 1 patient having intolerable pain for whom the PADN
procedure was not completed. There were 2 deaths during
the 3-month follow-up. One patient died from septic shock
87 days following the PADN procedure. This 42-year-old
Table 4 Assessment of Functional Capacity
Before
Following PADN
24 H 1 Week 1 Month 2 Months 3 Months
6MWD, m
PADN group 324  21 d 390  33 459  42* 487  47* 491  38*
Control group 358  30 d 361  36 365  38y 362  39z 364  38y
WHO class
PADN group 3.6  0.8y d 2.3  1 1.7  0.9 1.6  0.7 1.6  0.8
Control group 3.5  0.9y d 3.5  0.8y 3.5  0.8y 3.5  0.9y 3.2  0.4y
Class 3
PADN group 6 (46)y d 1 (7.6) 1 (7.6) 1 (7.6) 1 (7.6)
Control group 4 (50)y d 4 (50)y 4 (50)y 4 (50)y 4 (50)y
BORG index
PADN group 3.4  0.3 d 3.0  0.4 3.0  0.3 2.3  0.4* 2.3  0.4*
Control group 3.5  0.4 d 3.5  0.3 3.3  0.4 3.2  0.3y 3.3  0.3y
Class 3
PADN group 8 (62)y d 3 (23) 3 (23) 3 (23) 3 (23)
Control group 4 (50)y d 4 (50)y 4 (50)y 4 (50)y 4 (50)y
NT-BNP, pg/ml
PADN group 2,005  442z 1,502  419 1,234  322 910  205 837  204 822  201
Control group 1,993  407z 2,020  435z 1,992  387z 1,990  418z 2,001  411z 1,988  422z
All-cause death
PADN group d 0 0 0 1 (7.6) 1 (7.6)
Control group d 0 0 0 1 (12.5) 1 (12.5)
Rehospitalization
PADN group d 0 0 0 0 0
Control group d 0 5 (62.5)x 5 (62.5)x 5 (62.5)x 5 (62.5)x
Lung transplantation
PADN group d 0 0 0 0 0
Control group d 0 0 0 0 0
Values are mean  SD or n (%). *p<0.010,comparedwithbeforePADN. yp< 0.010, compared with following PADN. zp < 0.001, compared with following PADN. xp< 0.001, compared with following PADN.
6 MWD ¼ 6-min walk distance; BORG ¼ BORG dyspnea scoring; NT-BNP ¼ N-terminal brain natriuretic peptide; PADN ¼ pulmonary artery denervation; WHO ¼ World Health Organization.
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1098lady with IPAH was ﬁrst treated with bosentan for 3 months.
Bosentan was stopped because of severe liver damage, then
diuretics and sildenaﬁl were prescribed for 2.2 years. This
patient went for the PADN procedure and after the proce-
dure, the mean PAP was reduced from 59 mmHg at baseline
to 23 mm Hg at 2 months follow-up. Her 6MWT increased
from 134 m before, to 245 m post-PADN procedure. At
87 days after the PADN procedure, this patient developed
fever and severe fatigue. Her white blood cells increased to
2.2  109/l. During 8-h treatment at the local hospital,
a total of 2,000 ml of saline was infused, without an increase
in blood pressure (systolic blood pressure was between 70 and
78 mm Hg). Immediately after being transferred to our
hospital, the blood lactate level was 24.6 mmol/l, and the
patient was completely cyanotic. The mean PAP by right
heart catheterization was stable between 25 and 28 mm Hg.
The patient died after 4 h of treatment. Another patient from
the control group died from RV failure at 72 days.
Discussion
We report for the ﬁrst time, to our knowledge, the safety and
beneﬁt of PADN in the treatment of IPAH. The majorﬁnding is that PADN is safe and associated with signiﬁcant
hemodynamic improvements, resulting in a signiﬁcant in-
crease in functional capacity.
Up to the present time, the treatment for IPAH has
been directed at restoring the balance between vasodilation
(e.g., prostacyclin, nitric oxide, and vasoactive intestinal
peptide) and vasoconstriction (e.g., thromboxane A2,
endothelin, and serotonin), growth inhibitors, mitogenic
factors, and antithrombotic and prothrombotic factors
(1,2). Recently, several classes of drugs have been devel-
oped. These medications have been reported to be associ-
ated with mild-to-moderate improvements in clinical
symptoms, functional capacity, hemodynamics, and clinical
outcomes (18–21), suggesting that diverse pathological
pathways contribute to the progression of PAH and that
more effective therapy is needed. However, the severe side
effects are the more common reasons limiting the use of
these medications.
Mechanisms of PADN. Anatomic and pathological studies
have revealed marked hypertrophy of the muscular layer of the
PA in patients with PAH, suggesting active vasoconstriction
(1,2,22). Moreover, baroreceptor structures have been
described in the PA (4,5), but the controversies regarding the
JACC Vol. 62, No. 12, 2013 Chen et al.
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1099types of the afferent and efferent ﬁbers have existed for a long
time (4,5,23). Circulating catecholamine levels in PAH have
been reported to be either increased (24,25) or to remain
within normal limits (26,27). This discrepancy may be related
to the fact that pressure overload–induced failing RV in PAH
subjects via local mechanisms (28). This postulation was
veriﬁed by Velez-Roa et al. (29), who reported increased
sympathetic nerve trafﬁc in advanced PAH, a ﬁnding that
was further conﬁrmed by Wensel et al. (30). Furthermore,
Juratsch et al. (5) reported that the signiﬁcantly increased
PAP and PVR induced by balloon distension of the MPA
were completely abolished by surgical denervation of the
bifurcation of the MPA and chemical sympathectomy using
6-hydroxydopamine (a known mediator of adrenergic
nerves). These results suggested that the efferent limb of
this reﬂex is predominantly mediated via the adrenergic
nervous system.
Before our present study in humans, the dynamic change
of PA hemodynamic measurements was investigated in our
animal laboratory (7). The results showed that during
occlusion of left interlobar PA, PAP and PVR gradually
increased and reached peak values after 5 min, and that this
pressure response was completely abolished after PADN at
the MPA bifurcation level rather than at sites 5 mm distal
to the ostial. In this animal study, we also found that it was
somewhat difﬁcult to keep the tip of the conventional
ablation catheter in tight and constant contact with the PA
wall because of the movement of the PA with inspiration
and expiration. So we designed a dedicated PADN catheter
with a circular tip and appropriate diameter in order to
improve the stability and the constant contact with the PA
wall. With better and more reliable equipment, we per-
formed this ﬁrst-in-man study. The results showed that
PADN performance at the bifurcation area of the MPA
was associated with signiﬁcant reduction of PAP and PVR,
and signiﬁcant improvement of 6MWT. This ﬁnding
might raise concerns about the conventional pathogenesis
of PAH, and might suggest the effectiveness of PADN
for IPAH patients with unsatisfactory clinical response
to medication, a similar new understanding on the effect
of renal denervation for treatment of refractory hyperten-
sion (31).
Comparison with drug therapy. More than 25 randomized
control trials with >3,200 patients with PAH (IPAH, asso-
ciated PAH, chronic thromboembolic pulmonary hy-
pertension, and others) have been performed to test the effects
of a variety of drugs (32). The average improvement of func-
tional capacity as assessed using the 6MWTwas 35.61m, with
a range of 10 to þ108 m. This increase appeared to be an
improvement of approximately 10.8%, which was signiﬁcantly
lower than the 29% (absolute increase of 101 m) observed in
our study. Hemodynamic parameters were also investigated
in randomized control trials with drugs. The weighted mean
reduction in the mean PAP was 2.86 mm Hg, with a range
of 1.00 to 9.30 mm Hg. The weighted mean reduction in
the PVR was 520 dyne $ s $ cm5. These values aresigniﬁcantly different from the13 mmHg and822 dyne $
s $ cm5 improvements that were observed following PADN.
On the other hand, current medications had several limitations
for treatment of PAH, such as high cost, severe side effects,
complex intravenous or subcutaneous injection setup, and
unpredictable long-term effects. One special ﬁnding of our
study was that all medications (sildenaﬁl or bosentan) were
discontinued safely for all patients except for 1 who continued
to receive a diuretic after PADN. This might imply that there
is a “pure” effect of PADN itself on improvements in cardiac
function, hemodynamic measurements, and functional ca-
pacity. Of course, the toxic effect of medications prescribed
before the enrollment could not be excluded.
Clinical relevance. NT-BNP, the precursor of BNP, may
be a more sensitive measure of RV strain than BNP (32).
NT-BNP levels <1,400 pg/ml (33,34) indicate the worse
stage at which the PAH patients were, as in our study,
unresponsive to medications. The results from the current
study suggested that local sympathetic nerve activity
modulates PAH, and (PADN) by inducing local injury or
damage of this reﬂex arc localizing in the bifurcation area
of the MPA was associated with signiﬁcant reduction of
PAP and PVR, which led to improvement of cardiac
function and functional capacity. On the other hand,
although there are no PA perforation in this report, the
danger and the possibility of aneurysm formation should
be kept in mind. Thus, a learning curve is critical in order
to maintain the safety of the PADN procedure. Further-
more, taking hemodynamics and functional capacity into
consideration, the beneﬁt of the PADN procedure for
IPAH patients seems to become stable after 3 months
follow-up. Extended follow-up was required to assess
long-term improvement. Similar to all kinds of catheter-
based procedures, the PADN is possible to be repeat
performed. Finally, the improvement of PA compliance
might indicate the possibility of a change of pathological
features in distal PA segments, 1 of the main lesions in
IPAH patients (35).
Study limitations. Given the small numbers, possible bias
in patient selection and the fact that this is not a placebo-
controlled double-blind study, the discussion should be
further moderated to indicate that much more study is
required before this therapy can even be considered for
treating PAH. Although the results are promising and
intriguing, only carefully designed trials with controls and
appropriate blinding must be done in a much larger cohort
and at multiple centers before deﬁnitive conclusions about
efﬁcacy can be determined.
Conclusions
We report the effect of PADN on hemodynamics and
functional capacity in patients with PAH. Future studies
are needed in a randomized, multicenter setting with
a larger patient population, to conﬁrm these preliminary
ﬁndings.
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